Aeglea Biotherapeutics
NASDAQ: SYREacquired by Spyre TherapeuticsAustin, US · Founded 2015 · Delaware corporation · 10 employees on LinkedIn · 1 known investors
Find your way into Aeglea Biotherapeutics
379 people in our graph share verified history with the Aeglea Biotherapeutics team — schools, employers, funds. One of them is your warm intro.
Acquired by Spyre Therapeutics November 2023 · terms undisclosed — $210M concurrent financing (reverse merger, no traditional purchase price disclosed) · source ↗
Spyre Therapeutics develops monoclonal antibodies with extended half-lives targeting inflammatory bowel disease and rheumatic conditions including rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis. The company is advancing single-agent and combination antibody therapies designed to enable less frequent subcutaneous dosing while addressing unmet treatment needs in these immune-mediated diseases.
Founders & leadership
Aeglea Biotherapeutics was founded in 2015 by David G. Lowe and George Georgiou.
Board
Investors · 1
Reported raises · per SEC filings
Form D private placements$434M disclosed across 3 rounds · 2015–2023
▶$180MraisedDec 2023 · 30 investors · BiotechnologyRule 506(b)
- Cameron TurtleExecutive Officer, Director
- Tomas KiselakDirector
- Scott BurrowsExecutive Officer
- Laurie StelzerDirector
- Russell J. CoxDirector
- Peter HarwinDirector
- Alison LawtonDirector
- Michael HendersonDirector
- Heidy King-JonesExecutive Officer
- Jeffrey W. AlbersDirector
- Offering amount
- $180M
- Amount sold
- $180M
- Finders' fees
- $10.8M
- Placement agents
- Cowen and Company, LLC, Stifel, Nicolaus & Company, Incorporated, Guggenheim Securities, LLC, LifeSci Capital LLC, Jefferies LLC
- First sale
- Dec 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$210MraisedJul 2023 · 41 investors · BiotechnologyRule 506(b)
- Tomas KiselakDirector
- Peter HarwinDirector
- Michael HendersonDirector
- Cameron TurtleExecutive Officer
- Jonathan AlspaughExecutive Officer
- Alison LawtonDirector
- Ivana Magovcevic-LiebischDirector
- Hunter C, SmithDirector
- Russell J. CoxDirector
- Cortney CaudillExecutive Officer
- Offering amount
- $210M
- Amount sold
- $210M
- Finders' fees
- $12.6M
- Placement agents
- Cowen and Company, LLC, Guggenheim Securities, LLC, Jefferies LLC, Stifel, Nicolaus & Company, Incorporated
- First sale
- Jun 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$44MraisedMar 2015 · 54 investors · BiotechnologyRule 506(b)
- Charles N. YorkExecutive Officer
- David G. LoweExecutive Officer, Director
- Henry SkinnerDirector
- George GeorgiouDirector
- Armen ShanafeltDirector
- Offering amount
- $44M
- Amount sold
- $44M
- First sale
- Mar 2015
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed eventsSource: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Frequently asked questions
- What does Aeglea Biotherapeutics do?
- Spyre Therapeutics develops monoclonal antibodies with extended half-lives targeting inflammatory bowel disease and rheumatic conditions including rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis. The company is advancing single-agent and combination antibody therapies designed to enable less frequent subcutaneous dosing while addressing unmet treatment needs in these immune-mediated diseases.
- Who founded Aeglea Biotherapeutics?
- Aeglea Biotherapeutics was founded by David G. Lowe, George Georgiou in 2015.
- Who are Aeglea Biotherapeutics's investors?
- Aeglea Biotherapeutics's investors include RA Capital.
- How much funding has Aeglea Biotherapeutics raised?
- Aeglea Biotherapeutics has disclosed $434M raised across 3 rounds.
- Who acquired Aeglea Biotherapeutics?
- Aeglea Biotherapeutics was acquired by Spyre Therapeutics.
- Where is Aeglea Biotherapeutics headquartered?
- Aeglea Biotherapeutics is headquartered in Austin, US.